Hims & Hers Health, Inc. (HIMS)
| Market Cap | 6.54B |
| Revenue (ttm) | 1.48B |
| Net Income (ttm) | 126.04M |
| Shares Out | 222.17M |
| EPS (ttm) | 0.53 |
| PE Ratio | 55.35 |
| Forward PE | 45.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,427,679 |
| Open | 28.49 |
| Previous Close | 28.31 |
| Day's Range | 28.15 - 29.84 |
| 52-Week Range | 11.20 - 72.98 |
| Beta | 1.65 |
| Analysts | Buy |
| Price Target | 38.25 (+29.84%) |
| Earnings Date | May 5, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for HIMS stock is "Buy." The 12-month stock price forecast is $38.25, which is an increase of 29.84% from the latest price.
News
Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom, Analysts Say
Investors worry patients won't make that price leap and that Hims, which has built its business on affordable healthcare, will struggle to meet its revenue goal.
Hims & Hers shares rise as company adds Eli Lilly's Zepbound
CNBC's Brandon Gomez joins 'Closing Bell' to discuss Hims & Hers shares rising as company adds new weight-loss medications to platform.
Hims & Hers Expands Weight Loss Offering, Adds Lilly's Zepbound to Platform
The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.
Hims & Hers shares rise as company adds new weight-loss medications to platform
Hims & Hers Health is adding Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, to its platform. The company's GLP-1 offerings have e...
Hims & Hers to sell Lilly's Zepbound on its telehealth platform
Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform.
Here's why Hims & Hers stock price has crashed: buy the dip?
Hims & Hers stock price has imploded this year, erasing some of the gains made in 2024 when it became one of the top-performing companies in the US. HIMS has crashed to $33.35, down by over 54% from i...
Hims & Hers Health: Reaching Escape Velocity Goes Unnoticed By The Market
I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS' stoc...
The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide product. Its diversified portfolio in men's and wome...
Hims & Hers Health: Developing A Better Understanding
Hims & Hers Health has become one of the most popular growth stocks in the market today. After sharing with my readers a bullish perspective on the stock at ~$6/share in 2023, I'm back to provide a un...
Jumping Into The FDA Gamble: Initiating Hims & Hers With A Buy
Hims & Hers Health, Inc. stock surged to $68, and the subsequent 50% crash is the talk of the town. I'm eyeing it as a favorable high-risk, high-reward play. HIMS stock plummeted after the FDA halted ...
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Hims & Hers (HIMS) is a newfangled tele-health company that started to ride the waves of GLP-1 weight loss medications. As waves go, this one's given the stock a heck of ride; way up and then all the ...
Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers
MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs introduces RKLX and HIMZ, two 2X leveraged single-stock ETFs designed to provide amplified exposure to Rocket Lab USA, Inc. (NASDAQ: RKLB) and H...
Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase, and achieved $126 million in GAAP net income. The company's subscriber base reached 2.2 million, growin...
Hims & Hers to shut down dermatology business Apostrophe
Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday.
DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
NEW YORK , March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the ...
Hims and Hers just shut down its dermatology business after stock slump on FDA's weight-loss drug decision
Hims and Hers is shutting down the dermatology business it acquired in 2021, BI has learned. The company said it's closing skincare site Apostrophe to centralize its teledermatology offerings.
Hims & Hers: The Odds Are In Your Favor, Here's How To Take Advantage (Rating Upgrade)
Hims & Hers Health is now reasonably valued after its large drop, making it a cautious Buy due to its high growth potential. The company's revenue grew 69% YoY to $1.5 billion, driven by a 45% increas...
Novo Nordisk's Cheaper Wegovy Offering Is Bad News for Hims & Hers
The announcement comes weeks after the FDA declared that Wegovy is no longer in shortage.
Why Is Hims & Hers Health Stock Trading Lower On Wednesday?
Hims & Hers Health, Inc. HIMS stock is trading lower on Wednesday, with a session volume of 7.7 million compared to the average volume of 19.34 million, as per data from Benzinga Pro.
Hims & Hers' Fall From Grace Is Warranted - Still No Margin Of Safety
HIMS' steep correction is well warranted, given the expensive valuations and the headwinds from the now available FDA-approved GLP-1 therapies. However, we believe that the end of GLP-1 shortage is a ...
Hims & Hers: A Generational Dip-Buying Opportunity
HIMS stock is going bananas with the stock up nearly 200% YTD at one point. However, the stock sold off due to the FDA's announcement that semaglutide will be taken off the shortage list. While bears ...
Hims & Hers: Shortage-Driven Sell-Off Appears Overdone; Buy
Hims and Hers' stock dropped 25% due to the end of the semaglutide shortage, but the sell-off is seen as exaggerated. Despite the setback, Hims and Hers continue to show strong subscriber growth and p...
Hims & Hers: Down 45% In 5 Days, Is The Stock Still A Buy?
Hims & Hers Health is a promising disruptor in the $4T US healthcare market, aiming to become the most trusted health & wellness brand. Despite recent stock volatility, Hims & Hers' Q4 2024 report sho...
Hims & Hers Health: Focus On The Future, Not GLP-1s
Hims & Hers Health, Inc. reported strong growth, with Q4 sales up $80 million sequentially, yet HIMS stock fell due to GLP-1 business confusion. The online health and wellness platform guided to $2.3 ...
Hims & Hers shares plunge 28% on concerns over weight loss business, margins
Hims & Hers shares fell on Tuesday, a day after the company released fourth-quarter results that disappointed on gross margin and outlined changes to its weight loss business. The company reported $48...